Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.
A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
A semi-synthetic cephalosporin antibiotic.
A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects.
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
Small clusters of chemoreceptive and supporting cells located near the ARCH OF THE AORTA; the PULMONARY ARTERIES; and the CORONARY ARTERIES. The aortic bodies sense PH; CARBON DIOXIDE; and OXYGEN concentrations in the BLOOD and participate in the control of RESPIRATION. The aortic bodies should not be confused with the PARA-AORTIC BODIES in the abdomen (which are sometimes also called aortic bodies).
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.
A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.
Clavulanic acid and its salts and esters. The acid is a suicide inhibitor of bacterial beta-lactamase enzymes from Streptomyces clavuligerus. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.
A cephalosporin antibiotic.
Substances that reduce the growth or reproduction of BACTERIA.
Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.
Gram-negative aerobic cocci of low virulence that colonize the nasopharynx and occasionally cause MENINGITIS; BACTEREMIA; EMPYEMA; PERICARDITIS; and PNEUMONIA.
Semisynthetic broad-spectrum cephalosporin.
A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Structure-function studies of Ser-289 in the class C beta-lactamase from Enterobacter cloacae P99. (1/96)

Site-directed mutagenesis of Ser-289 of the class C beta-lactamase from Enterobacter cloacae P99 was performed to investigate the role of this residue in beta-lactam hydrolysis. This amino acid lies near the active site of the enzyme, where it can interact with the C-3 substituent of cephalosporins. Kinetic analysis of six mutant beta-lactamases with five cephalosporins showed that Ser-289 can be substituted by amino acids with nonpolar or polar uncharged side chains without altering the catalytic efficiency of the enzyme. These data suggest that Ser-289 is not essential in the binding or hydrolytic mechanism of AmpC beta-lactamase. However, replacement by Lys or Arg decreased by two- to threefold the kcat of four of the five beta-lactams tested, particularly cefoperazone, cephaloridine, and cephalothin. Three-dimensional models of the mutant beta-lactamases revealed that the length and positive charge of the side chain of Lys and Arg could create an electrostatic linkage to the C-4 carboxylic acid group of the dihydrothiazine ring of the acyl intermediate which could slow the deacylation step or hinder release of the product.  (+info)

Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. (2/96)

A prospective, open-label, randomized study was conducted in order to determine the bacteriologic efficacies of cefaclor and azithromycin in acute otitis media (AOM). Tympanocentesis was performed on entry into the study and 3 to 4 days after initiation of treatment. Bacteriologic failure after 3 to 4 days of treatment with both drugs occurred in a high proportion of culture-positive patients, especially in those in whom AOM was caused by Haemophilus influenzae (16 of 33 [53%] of those treated with azithromycin and 13 of 34 [52%] of those treated with cefaclor). Although a clear correlation of the persistence of the pathogen with increased MICs of the respective drugs could be demonstrated for Streptococcus pneumoniae, no such correlation was found for H. influenzae. It is proposed that susceptibility breakpoints for H. influenzae should be considerably lower than the current ones for both cefaclor and azithromycin for AOM caused by H. influenzae.  (+info)

Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. (3/96)

There is evidence that macrolide antibiotics are effective in the treatment of chronic airway inflammatory diseases, probably through actions other than their antibacterial properties. In order to determine whether macrolides affect the nitric oxide-generating system in the respiratory tract, rat pulmonary alveolar macrophages (PAMs) were studied in vitro. The release of NO was assessed by direct measurement with a specific amperometric sensor for this molecule, and the expression of type II NO synthase (NOS) messenger ribonucleic acid (mRNA) was determined by Northern blotting. Incubation of PAMs with lipopolysaccharide from Escherichia coli and recombinant human interferon-gamma caused release of NO, which was accompanied by induction of type II NOS mRNA. The release of NO was reduced by coincubation of cells with the macrolides erythromycin, clarithromycin and josamycin in a concentration-dependent manner, the maximal inhibition being 73+/-10, 81+/-6 and 84+/-9%, respectively, but was not altered by amoxycillin or cefaclor. These macrolides likewise inhibited the induction of type II NOS mRNA, whereas no inhibitory effects were observed with amoxycillin or cefaclor. These results suggest that macrolide antibiotics specifically inhibit type II NO synthase gene expression and consequently reduce NO production by rat pulmonary alveolar macrophages, which might result in attenuation of airway inflammation.  (+info)

Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae. (4/96)

beta-Lactamase production in Canadian isolates of Haemophilus influenzae has remained relatively constant (25-35%) over the last decade despite increasing cefaclor resistance (MIC >/= 32 mg/L). TEM (294/324, 90.7%) and ROB-1 (30/324, 9.3%) prevalence rates among 324 isolates of H. influenzae obtained from across Canada in 1997-1998 were similar (P > 0.05) to previously published reports. However, 66. 7% (26/39) of cefaclor-resistant isolates were ROB-1-positive (P < 0. 001) and the remaining four ROB-1-positive isolates were cefaclor-intermediate (MIC 16 mg/L). Susceptibilities to loracarbef (P < 0.001) and cefprozil were also reduced in the presence of ROB-1 while the activities of cefuroxime, cefotaxime, cefixime and imipenem were similar in both TEM- and ROB-1-positive solates.  (+info)

Cefaclor, a cephalosporin antibiotic, delays gastric emptying rate by a CCK-A receptor-mediated mechanism in the rat. (5/96)

Studies in vitro suggest that cephalosporin antibiotics release the gut hormone cholecystokinin. Cholecystokinin is known to inhibit gastric emptying. Here we examine the effects of cefaclor on gastric emptying and intestinal motility. Male Sprague-Dawley rats were fitted with gastric cannulas. Following a 3-week recovery, the rate of gastric emptying of saline, peptone (4.5%) or cefaclor was determined after instillation into the gastric cannula, while intestinal transit was measured by using the propagation of arabic gum + charcoal mixture given intraduodenally. Gastric emptying of saline was significantly delayed by the addition of cefaclor (3, 10, 30 or 100 mM). The CCK-A antagonist SR-27897B (1 mg kg(-1), i.p.) reversed the delay induced by 10 mM cefaclor, whereas the CCK-B antagonist CI-988 (1 mg kg(-1), i.p.) had no significant effect. In capsaicin-treated rats, 10 mM cefaclor emptied more rapidly than in vehicle-treated animals. Thirty-minute intestinal transit was increased at 30 and 100 mM of cefaclor, while the gastric acid secretion following cefaclor instillation was no different than the group which received saline. The cephalosporin antibiotic cefaclor appears to be a potent stimulant of CCK release from gut endocrine cells, resembling the effects of peptone. Cefaclor delays gastric emptying via capsaicin-sensitive afferent pathways, which involve CCK-A receptor interaction.  (+info)

Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase. (6/96)

Stopped-flow tryptophan fluorescence under single turnover and pseudo-first-order conditions has been used to investigate the kinetic mechanism of beta-lactam hydrolysis by the Stenotrophomonas maltophilia L1 metallo-beta-lactamase. For the cephalosporin substrates nitrocefin and cefaclor and the carbapenem meropenem, a substantial quench of fluorescence is observed on association of substrate with enzyme. We have assigned this to a rearrangement event subsequent to formation of an initial collision complex. For the colorimetric compound nitrocefin, decay of this dark inter- mediate represents the overall rate-determining step for the reaction and is equivalent to decay of a previously observed state in which the beta-lactam amide bond has already been cleaved. For both cefaclor and meropenem, the rate-determining step for hydrolysis is loss of a second, less quenched state, in which, however, the beta-lactam amide bond remains intact. We suggest, therefore, that the mechanism of hydrolysis of nitrocefin by binuclear metallo-beta-lactamases may be atypical and that cleavage of the beta-lactam amide bond is the rate-determining step for breakdown of the majority of beta-lactam substrates by the L1 enzyme.  (+info)

E test for studying in vitro activity of seven antimicrobial agents against penicillin-susceptible and penicillin-resistant pneumococci. (7/96)

OBJECTIVE: To evaluate the comparative activity of seven oral antimicrobial agents against 100 strains of Streptococcus pneumoniae (S. pneumoniae). METHODS: Total 100 strains of S. pneumoniae were collected from general hospitals in Beijing from June 1996 to June 1997. E test method was used to detect the minimum inhibitory concentration (MIC) values of the following seven drugs against S. pneumoniae: penicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, ceftriaxone, azithromycin and ofloxacin. The breakpoint of susceptibility categories was defined according to NCCLS. RESULTS: 74% of isolates were susceptible (S, MIC 0.06 mg/L) to penicillin, and 5% were penicillin resistant (R, MIC 2 mg/L). The intermediately resistant (I, MIC 0.1-1 mg/L) rate to penicillin was 21%. The total rates of R or I were 26% for penicillin, 6% for both amoxicillin/clavulanate and ceftriaxone, 9% for cefuroxime, 66% and 68% for azithromycin and ofloxacin respectively. Overall 94%, 94% and 91% of the pneumococcal isolates were susceptible to amoxicillin/clavulanate, ceftriaxone and cefuroxime respectively. S. pneumoniae was highly resistant to azithromycin tested as a representative of macrolides (MIC50 and MIC90 both > 256 mg/L, R rate 66%), and had a highly intermediately resistant rate to ofloxacin (I rate 62%). CONCLUSIONS: Our data suggest that in vitro activity of oral amoxicillin/clavulanate was as good as ceftriaxone and cefuroxime. It can be considered as an alternative compound in the treatment of community acquired pneumoniae and other respiratory tract infections caused by multiresistant S. pneumoniae.  (+info)

Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor. (8/96)

The clinical use of cefaclor has been shown to enrich Haemophilus influenzae populations harboring cefaclor-hydrolyzing ROB-1 beta-lactamase. Such a selective process may lead to the increased use of extended-spectrum cephalosporins or beta-lactams plus beta-lactamase inhibitors and, eventually, resistance to these agents, which has not previously been observed in H. influenzae. In order to establish which bla(ROB-1) mutations, if any, could confer resistance to extended-spectrum cephalosporins and/or to beta-lactamase inhibitors, a plasmid harboring bla(ROB-1) was transformed into hypermutagenic strain Escherichia coli GB20 (DeltaampC mutS::Tn10), and this construct was used in place of H. influenzae bla(ROB-1). Strain GB20 with the cloned gene was submitted to serial passages in tubes containing broth with increasing concentrations of selected beta-lactams (cefotaxime or amoxicillin-clavulanate). Different mutations in the bla(ROB-1) gene were obtained during the passages in the presence of the different concentrations of the selective agents. Mutants resistant to extended-spectrum cephalosporins harbored either the Leu169-->Ser169 or the Arg164-->Trp164 substitution or the double amino acid change Arg164-->Trp164 and Ala237-->Thr237. ROB-1 mutants that were resistant to beta-lactams plus beta-lactamase inhibitors and that harbored the Arg244-->Cys244 or the Ser130-->Gly130 replacement were also obtained. The cefaclor-hydrolyzing efficiencies of the ROB-1 variants were strongly decreased in all mutants, suggesting that if bla(ROB-1) mutants were selected by cefaclor, this drug would prevent the further evolution of this beta-lactamase toward molecular forms able to resist extended-spectrum cephalosporins or beta-lactamase inhibitors.  (+info)

... has also been reported to cause a serum sickness-like reaction in children. Cefaclor is contraindicated in case of ... Cefaclor is active against many bacteria, including both Gram-negative and Gram-positive organisms. Cefaclor is frequently used ... Cefaclor is passed into the breast milk in small quantities, but is generally accepted to be safe to take during breastfeeding ... Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical ...
... is a synthetic "carba" analog of cefaclor, and is more stable. Loracarbef received FDA approval in 1991 and it was ...
Cefaclor however has a Cl group at position C-3 which gives it better binding to PBP and thus better antimicrobial activity. ... The 7-phenyl-glycine makes it orally available and the chlorine at position C-3 makes it as active as Cefaclor. An important ... There is not an agreement on classifying Cefaclor as a first generation cephalosporin because of the Cl group at the C-3 ...
For example, the fourth generation of cephalosporins is not recognized as such in Japan.[citation needed] In Japan, cefaclor is ... but the use of cefaclor, cefadrocil, cefalexin, and cefradine should be avoided. Overall, the research shows that all beta ...
127 Agents that have been implicated in serum sickness-like reactions include cefaclor, amoxicillin, sulfonamides, ...
... cefaclor, piracetam, vaccines, and antidiabetic drugs. The antidiabetic sulphonylurea glimepiride, in particular, has been ...
... cefaclor (INN) cefadroxil (INN) Cefadyl cefalexin (INN) cefaloglycin (INN) cefalonium (INN) cefaloram (INN) cefaloridine (INN) ...
... cefaclor, cefprozil Cefaclor Cefamandole Cefuroxime Cefotetan Cefoxitin Cefixime Cefotaxime Cefpodoxime Ceftazidime Ceftriaxone ...
... cefaclor MeSH D02.065.589. - cefadroxil MeSH D02.065.589. - cefatrizine MeSH D02.065.589.099. ...
... second generation cephalosporins such as cefaclor Klebsiella pneumoniae Escherichia coli Pseudomonas aeruginosa - ciprofloxacin ...
... cefaclor, cefazoline, cefuroxime, and cefdinir), oxacillin, and most macrolides. Most isolated P. penneri strains are multiple- ...
Cefacetrile J01DB11 Cefroxadine J01DB12 Ceftezole J01DC01 Cefoxitin J01DC02 Cefuroxime J01DC03 Cefamandole J01DC04 Cefaclor ...
... cefaclor 1980 - cefmetazole 1980 - cefotaxime 1980 - piperacillin 1981 - co-amoxiclav (amoxicillin/clavulanic acid) 1981 - ...
Cefaclor Extended Release Tablets package insert / prescribing information for healthcare professionals. Includes: indications ... Cefaclor Extended Release Tablets Description. Cefaclor, USP, the active ingredient in cefaclor extended-release tablets USP, ... Each cefaclor extended-release tablet contains cefaclor monohydrate equivalent to 500 mg (1.36 mmol) anhydrous cefaclor. In ... The cefaclor extended-release tablet formulation of cefaclor is pharmacokinetically different from the cefaclor immediate- ...
Cefaclor: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Take cefaclor until you finish the prescription, even if you feel better. If you stop taking cefaclor too soon or skip doses, ... Before taking cefaclor,. *tell your doctor and pharmacist if you are allergic to cefaclor, other cephalosporin antibiotics such ... Take cefaclor exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. ...
Cefaclor. 54.4. 48.2. 53.6. 57.0. 52.7. 0.241. 1.060 (0.962-1.167). Cefepime. 2.6. 1.0. 0.0. 2.0. 1.4. 0.287. 0.790 (0.513- ...
The strain was resistant to penicillin, cefotaxime, cefaclor, chloramphenicol, erythromycin, trimethoprim-sulfamethoxazole, ...
27] cefaclor (most common), minocycline, propranolol, streptokinase, sulfonamides, and NSAIDs. * SJS [28, 29, 30] - Allopurinol ...
cefaclor. cefaclor increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of ... cefaclor. Minor (1)cefaclor increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. ...
Cefaclor D2.886.675.966.500.249.200.155 D2.886.665.74.200.155. D4.75.80.875. Cefadroxil D2.886.675.966. ...
Stability of the crystalline form of cefaclor monohydrate and its pharmaceutical preparations. Beata Medenecka, Anna Jelińska, ...
From Sep 2018 MWF - a.m. Augmentin Duo 440mg + 150mg Biaxsig (roxithromycin). p.m. Cefaclor (375mg) + Klacid 125mg + LDN 3mg + ... From Sep 2018 MWF - a.m. Augmentin Duo 440mg + 150mg Biaxsig (roxithromycin). p.m. Cefaclor (375mg) + Klacid 125mg + LDN 3mg + ...
Cefaclor is used at how simple this really. Although no formal chewable tablets are Read More Rimadyl tiotropium bromide ...
Amoxicillin, ampicillin, cefaclor, cefalexin, ciprofloxacin, chlortetracycline, clarithromycin, difloxacine, doxycycline, ...
Can cranberry juice be a substitute for cefaclor prophylaxis in children with vesicoureteral reflux? Pediatr Int. 2009;51:433-4 ...
Single-dose cefaclor therapy of urinary tract infection. Evaluation of antibody-coated bacteria test and C-reactive protein ...
Cefaclor - A Cluster of Adverse Reactions. Murray, D. L., Singer, D. A., Singer, A. B. & Veldman, J. P., Oct 23 1980, In: New ... Cefaclor reactions. Murray, D. L., Jan 1 1985, In: Pediatric Infectious Disease. 4, 6, 1 p.. Research output: Contribution to ...
Cefaclor Anhydrous. Cefaclor Monohydrate. Keclor. Lilly 99638. S 6472. S-6472. S6472. ...
Cefaclor 250mg Capsules. Generic Equivalent to Ceclor. SKU: *CEFACLORCAP250. Found in: Drugs A - D , Prescription Medicine by ...
... cefaclor), Duricef (cefadroxil) Cleocin (clindamycin) Erythromycin (all forms) Zithromax (azithromycin) Sulfa drugs (until near ...
The first stop for professional medicines advice
Group Side Chainsa 2 Cephalexin Cefotaxime Cefuroxime Cefotetan Cefaclor Ceftibuten Cefadroxil Cephalothin Cefoxitin ...
The only time that surgery is used as an adjunctive treatment in this case is ceclor the same as cefaclor those who have a ... The most basic and most controversial question surrounding the Oregon plan is ceclor the same as cefaclor afford to pay for all ... If the tumor is ceclor the same as cefaclor to the lining or is malignant, then a patients survival expectancy is only 10 ... The primary use of an external catheter in a patient of esophageal stricture is ceclor the same as cefaclor of the catheter ...
Cefaclor Code System Concept Status. Published. Code System Preferred Concept Name. Cefaclor. ...
Features and benefits of each system. Improvement via modification of drug release of active pharmaceutical ingredient.. Sustained Release. Pharmaceutical actives release in the body system are delayed thus prolonging and improving time duration of the drug.. Instant Release. Pharmaceutical actives release in the body system are immediate thus improving drugs onset of action.. Bi-Layered Tablet. Pharmaceutical actives are compartmentalized preventing drug-drug reactions of combination products. Bi-layering can also function as modifier of drug release.. Tablet in Tablet. Pharmaceutical actives in tablet are enclosed in another tablet for modification of drug release or for protection purposes.. Mouth-Dissolving Tablet. Pharmaceutical actives are enclosed in a specialized dosage form suitable for fast absorption in the buccal region.. Tablet in Capsule. Pharmaceutical actives in tablet are enclosed in another capsule for modification of drug release or for protection purposes.. Pellet ...
  • The only time that surgery is used as an adjunctive treatment in this case is ceclor the same as cefaclor those who have a severe form of the disease. (
  • Each capsule contains cefaclor monohydrate equivalent to 250 mg (0.68 mmol) or 500 mg (1.36 mmol) anhydrous cefaclor. (
  • Cefaclor, USP, is chemically designated as 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid monohydrate. (
  • Each cefaclor extended-release tablet contains cefaclor monohydrate equivalent to 500 mg (1.36 mmol) anhydrous cefaclor. (
  • After mixing, each 5 mL of Cefaclor for Oral Suspension will contain cefaclor monohydrate equivalent to 250 mg (0.68 mmol) anhydrous cefaclor. (
  • As with other cephalosporins, the bactericidal action of cefaclor results from inhibition of cell-wall synthesis. (
  • In contrast, when cefaclor extended-release tablets are taken without food, the AUC is 23% lower while the C max is 67% lower and occurs 0.6 hours later, using an equivalent milligram dose of cefaclor immediate-release capsules as a reference. (
  • Healthy geriatric volunteers (≥ 65 years old) who received a single 750 mg dose of cefaclor extended-release tablets had 40%-50% higher AUC and 20% lower renal clearance values when compared to healthy adult volunteers less than 45 years of age. (
  • A single dose of cefaclor 250 mg was given orally to 2 nursing mothers. (
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor and other antibacterial drugs, cefaclor should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (
  • In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. (
  • Serum pharmacokinetic parameters for cefaclor extended-release tablets and cefaclor immediate-release capsules are shown in the table below. (
  • Cefaclor Capsules, USP are a semisynthetic cephalosporin antibiotic for oral administration. (
  • Cefaclor, USP, the active ingredient in cefaclor extended-release tablets USP, is a semisynthetic cephalosporin antibiotic for oral administration. (
  • Cefaclor is in a class of medications called cephalosporin antibiotics. (
  • however, when cefaclor immediate-release capsules are taken with food, the C max is decreased. (
  • When cefaclor extended-release tablets are taken with food, the AUC is 10% lower while the C max is 12% lower and occurs 1 hour later compared to cefaclor immediate-release capsules. (
  • Also tell your doctor if you are allergic to any of the ingredients in cefaclor capsules, extended release tablets, or suspension. (
  • Amoxicillin and cefaclor are two of the widely used beta-lactam antibiotics in the treatment of urinary tract infections. (
  • 7. Cefaclor versus ampicillin for outpatient treatment of urinary tract infections. (
  • Single-dose cefaclor therapy of urinary tract infection. (
  • Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. (
  • The objective of the current study was to examine the kinetics of amoxicillin and cefaclor interactions with human renal transporters human organic anion transporter 1 (hOAT1), human peptide transporter 1 (hPepT1), and human peptide transporter 2 (hPepT2) in detail, both as substrates and as inhibitors. (
  • 1. Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment. (
  • Resistance to cefaclor is primarily through hydrolysis of beta-lactamases, alteration of penicillin binding proteins (PBPs) and decreased permeability. (
  • Certain medicines (such as penicillin, cefaclor , and sulfa) can cause a similar reaction. (
  • The cefaclor extended-release tablets formulation of cefaclor differs pharmacokinetically from the immediate-release formulation of cefaclor. (
  • The extent of absorption (AUC) and the maximum plasma concentration (C max ) of cefaclor from cefaclor extended-release tablets are greater when the extended-release tablet is taken with food. (
  • No drug accumulation was noted when cefaclor extended-release tablets were given twice daily. (
  • Therefore, cefaclor extended-release tablets should be taken with food. (
  • if you are taking antacids that contain magnesium or aluminum, take them 1 hour before or 1 hour after cefaclor extended release tablets. (
  • Cefaclor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (
  • The cefaclor extended-release tablet formulation of cefaclor is pharmacokinetically different from the cefaclor immediate-release capsule formulation of cefaclor. (
  • Cefaclor comes as a capsule, an extended-release (long-acting) tablet, and a suspension (liquid) to take by mouth. (
  • Cefaclor is inactive against methicillin-resistant staphylococci, β lactamase-negative, ampicillin-resistant strains of H. influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility to this agent. (
  • Antibiotics such as cefaclor will not work for colds, flu, or other viral infections. (
  • If you stop taking cefaclor too soon or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics. (
  • Amoxicillin and cefaclor competitively inhibited hPepT2-mediated [(3)H]glycylsarcosine uptake (K(i) = 733 and 65 muM, respectively), whereas much lower affinity for hPepT1 was observed with both antibiotics. (
  • Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. (
  • 10. Therapy with cefaclor: analysis of infections in 189 French patients. (
  • Cefaclor is acceptable in nursing mothers. (
  • In a telephone follow-up study, 5 nursing mothers reported taking cefaclor (dosage unspecified). (
  • are resistant to cefaclor. (
  • Cefaclor is inactive against methicillin-resistant staphylococci. (
  • Amoxicillin and cefaclor inhibited hOAT1-mediated [(3)H]para-aminohippuric acid uptake (K(i) = 11.0 and 1.15 mM, respectively). (
  • Direct uptake studies demonstrated that amoxicillin and cefaclor were transported by hPepT1 and hPepT2. (
  • Limited information indicates that maternal cefaclor produces low levels in milk which are not expected to cause adverse effects in breastfed infants. (
  • Quantitative on-flow LC/NMR has been diffusely reflected contains vibrational information on relative purities and cefaclor impurities levels. (
  • You should begin to feel better during the first few days of treatment with cefaclor. (
  • Takase Z, Shirafuji H, Uchida M. Clinical and laboratory studies of cefaclor in the field of obstetrics and gynecology. (
  • Cefaclor is no longer marketed in the United States. (
  • The journal Evidencias en Pediatría does not demand from the authors the donation of their right on their manuscripts as a requisite to publish them. (
  • The journal Evidencias en Pediatría (Evidences in Pediatrics) recognizes as inalienable the intellectual and moral rights of the authors concerning the content of their published manuscripts. (
  • The journal Evidencias en Pediatría (EP / Evidences in Pediatrics) therefore, accepts that the authors could deposit, at institutional repositories or personal websites, an electronic copy of the revised and finally accepted version of the manuscript once it has been already published. (
  • This deposit will be done under the responsibility of the authors and specifically mention the original source (website of the journal Evidencías en Pediatría ) where the original version can be found. (
  • The property and rights of the published manuscripts, in its final format, are reserved to and are shared by the journal Evidencias en Pediatría (Evidences in Pediatrics) and the authors. (
  • This graph shows the total number of publications written about "Cefaclor" by people in this website by year, and whether "Cefaclor" was a major or minor topic of these publications. (
  • Below are the most recent publications written about "Cefaclor" by people in Profiles. (